Exercise of Options, Issue of Equity and TVR

C4X Discovery Holdings PLC

18 August 2023

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company") 

Exercise of Options, Issue of Equity and Total Voting Rights

18 August 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces it has issued 107,500 ordinary shares of 1p each in the Company ("New Ordinary Shares") following the exercise of options by certain employees of the Company.

Admission and Total Voting Rights

Application has been made for the 107,500 New Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 24 August 2023. The New Ordinary Shares will rank pari passu with the existing ordinary shares. 

Total Voting Rights

Following the issue of the New Ordinary Shares, the Company's issued share capital now consists of 252,227,097 ordinary shares. Accordingly, the figure of 252,227,097 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]

Notes to Editors:

 About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced candidate molecule design and patient stratification capabilities, generating small molecule drug candidates across multiple disease areas focused on immuno-inflammation.  Our commercially attractive portfolio ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have three commercially partnered programmes with one candidate in clinical development.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.

 

END